| Identification | Back Directory | [Name]
Formoterol fumarate | [CAS]
43229-80-7 | [Synonyms]
YM 08316
NSC 299587
FarMeterol
CGP 25827A
Aformoterol
CGP-25827A-e
Fumarate dihydrate
FORMAMIDE FUMARATE
ForMaterol FuMarate
FORMATEROL FUMATATE
FORMOTEROL FUMARATE
Eformoterol fumarate
FORMOTEROL HEMIFUMARATE
Formoterol fumarate JP13
ForMoterol FuMarate EP/USP
Formoterol fumarate 50 gram
BD-40A, Atock, Foradil, Oxeze
Formoterol dihydrate fumarate
Formoterol & Formoterol Fumarate
FORMOTEROL FUMARATE, EP STANDARD
ForMoterol FuMarate Dihydrate API
(R*,R*)-N-[2-HYDROXY-5-[1-HYDROXY-2-[[2
FORMOTEROL FUMARATE, FOR SYSTEM SUITABILITY EP STANDARD
o)ethyl)phenyl)-,(e)-2-butenedioate(2:1)(salt),dihydrate
FORMOTEROL FUMARATE, FOR IMPURITY D IDENTIFICATION EP STANDARD
formamide,n-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amin
(R*,R*)-N-[2-HYDROXY-5-[1-HYDROXY-2-[[2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]PHENYL]FORMAMIDE FUMARATE
N-(2-hydroxy-5-((S)-1-hydroxy-2-((S)-1-(4-methoxyphenyl)propan-2-ylamino)ethyl)phenyl)formamide hemifumaric acid
(R*,R*)-(+)-N-[2-HYDROXY-5-[1-HYDROXY-2-[[2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-PHENYL]FORMAMIDE FUMARATE
(+/-)-(R*,R*)-N-[2-HYDROXY-5-[1-HYDROXY-2-[[2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]PHENYL] FORMAMIDE HEMIFUMARATE
(R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate (2:1) salt
n-[2-hydroxy-5-[[(1rs)-1-hydroxy-2-[[(1rs)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (e)-2-butenedioate
rel-N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide Fumarate Dihydrate
Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-, (E)-2-butenedioate (2:1) (salt)
Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*,R*)-(+-)-, (E)-2-butenedioate (2:1) (salt)
Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, rel-, (2E)-2-butenedioate (2:1) (salt)
Formoterol fumarate N-[2-Hydroxy-5-[[(1RS)-1-hydroxy-2-[[(1RS)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (E)-2-butenedioate
Formoterol monohydrate hemifumarate salt, (R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C42H52N4O12 | [MDL Number]
MFCD03093863 | [MOL File]
43229-80-7.mol | [Molecular Weight]
804.88 |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Solid | [Melting point ]
138-140°C | [storage temp. ]
Room temperature | [solubility ]
Slightly soluble in water, soluble in methanol, slightly soluble in 2-propanol, practically insoluble in acetonitrile. | [form ]
neat | [pka]
pKa1 7.9; pKa2 9.2(at 25℃) | [color ]
White to off-white | [λmax]
284nm(lit.) | [Merck ]
14,4245 | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid | [Uses]
A potent β2-AR agonist | [Uses]
A selective 2-adrenergic receptor agonist. Used as an antiasthmatic | [Uses]
antiasthmatic;?2-agonist | [Uses]
long-acting β 2-agonist, anti-asthmatic | [Description]
Formoterol fumarate is a β2-selective adrenergic
agonist useful in the treatment of bronchial asthma.
It s potency and duration of action a r e reported to
exceed those of salbutamol, as is its ability to inhibit allergic and non-allergic histamine release. | [Originator]
Yarnanouchi (Japan) | [Definition]
ChEBI: (S,S)-formoterol fumarate is a fumarate salt prepared from (S,S)-formoterol by reaction of one molecule of fumaric acid for every two molecules of (S,S)-formoterol. It contains a (S,S)-formoterol(1+). It is an enantiomer of an arformoterol fumarate. | [Brand name]
Foradil (Novartis);ATOCK. | [Mechanism of action]
This is believed to result from formoterol's greater water solubility, allowing it to get to the receptor sites faster, whereas its moderate lipophilicity keeps it in the lungs longer. It is indicated for the long-term maintenance treatment of asthma and for patients with symptoms of nocturnal asthma who require regular treatment with inhaled, short-acting, β2-agonists. It is not indicated for patients whose asthma can be managed by occasional use of inhaled, short-acting, β2-agonists. Formoterol is available only as a powder in a capsule for administration via the aerosolizer. Patients should be cautioned not to take the capsules orally and to keep them in a safe place to avoid accidental oral administration. | [Clinical Use]
Formoterol has a β-directing N-isopropyl-p-methoxyphenyl group and a unique m-formamide and p-hydroxyphenyl ring, which provides selectivity for β2-receptors. It is resistant to MAO and COMT, making it a long-acting agonist. Formoterol has a more rapid onset as compared to salmeterol while maintaining the same long duration of action. | [storage]
Store at RT | [References]
1) Anderson et al. (1993), Formoterol: pharmacology, molecular basis of agonism and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator; Life Sciences, 52 2145
2) Teng et al. (2005), Structure-activity relationship study of novel necroptosis inhibitors; Bioorg. Med. Chem. Lett., 15 5039
3) Noguchi et al. (2015), Effect of beta2-adrenergic agonist on eosinophil adhesion, superoxide anion generation, and degranulation; Allergol. Int., 64 S46
4)Busquets et al. (2004), Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting; Cancer Res., 64 6725
5) O’Neill et al. (2020), Pharmacological targeting of ?2-adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson’s disease; Br. J. Pharmacol., 177 282 |
| Safety Data | Back Directory | [RIDADR ]
3249 | [RTECS ]
LQ2988000 | [HazardClass ]
6.1(b) | [PackingGroup ]
II | [Toxicity]
LD50 in male, female, rats, mice (mg/kg): 3130, 5580, 6700, 8310 orally; 98, 100, 72, 71 i.v.; 1000, 1100, 640, 670 s.c.; 170, 210, 240, 210 i.p. (Yoshida) |
|
|